Mentors in Medicine Series on Applied Precision Medicine: Focus on Treating CNS Tumors and Metastases

Release Date: September 16, 2021
Expiration Date: September 16, 2022

Activity Overview

Mentors in Medicine Series on Applied Precision Medicine: Focus on Treating CNS Tumors and Metastases is a CME-certified, case-based, live webcast. This educational activity provides practicing oncologists with expert perspectives on incorporating diagnostic testing into everyday clinical practice to optimize management of their patients with central nervous system (CNS) tumors or metastases. Renowned faculty analyze recent clinical trial evidence to optimize therapeutic strategies, using real patient cases as a starting point. Each case includes an expert analysis of Show Me the Data^® as well as Key Takeaways 4 Tomorrow that can be applied immediately in the oncology clinical practice.
 
This educational activity is an archive of the live virtual webcast held on September 9, 2021.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Janssen Scientific Affairs, LLC; Pharmacyclics LLC, an AbbVie Company; and Seagen Inc.

Target Audience

This educational program is intended for oncologists and hematologists involved in the treatment of patients with primary CNS tumors or brain metastases. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of CNS tumors and metastases are also invited to attend.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Incorporate diagnostic testing and/or therapy selection for treatment of CNS tumors and metastases
• Analyze recent data on the efficacy and safety of therapeutic options for the treatment of CNS tumors and metastases
• Apply optimal management strategies in the treatment of patients with CNS tumors and metastases based on recent clinical trial findings

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible entities.

Series Chair

Andre Goy, MD
Physician-in-Chief, Hackensack Meridian Health Oncology Care Transformation Service
Chairman & Chief Physician Officer, John Theurer Cancer Center
Lydia Pfund Chair for Lymphoma
Academic Chairman Oncology, Hackensack Meridian School of Medicine
Professor of Medicine, Georgetown University
Hackensack, NJ

Disclosures: Grant/Research Support: PI: Acerta Pharma, AstraZeneca, Celgene Corporation, Constellation Pharmaceuticals, Genentech/Hoffmann-La Roche, Infinity Pharmaceuticals, Infinity Pharmaceuticals/Verastem Oncology, Janssen Pharmaceuticals, Karyopharm, Kite Pharma, Pharmacyclics; Consultant: Acerta Pharma, Celgene Corporation, Gilead Sciences, Janssen Pharmaceuticals, Kite Pharma, Xcenda; Stock/Shareholder: COTA; Other: Honoraria: AstraZeneca, Celgene Corporation, Gilead Sciences, Kite Pharma, Xcenda; Advisory: AstraZeneca, COTA, Elsevier’s PracticeUpdate, Gilead Sciences, Janssen Pharmaceuticals, Kite Pharma.

Moderator

Samuel A. Goldlust, MD
Pitkin Endowed Chair, Neuro Oncology
Medical Director, Brain & Spine Institute
John Theurer Cancer Center
Hackensack Meridian Health
Hackensack, NJ

Disclosures: Consultant: Boston Biomedical, Novocure; Stock/Shareholder: COTA; Other: Travel or meals: Novocure, Caris Life Sciences, Kyowa Kirin.

Faculty

Nicholas J. DeNunzio, MD, PhD
Director of Proton Therapy
Department of Radiation Oncology
John Theurer Cancer Center
Hackensack Meridian Health
Hackensack, NJ

Disclosures: No relevant financial relationships with ineligible companies.

George J. Kaptain, MD, FAANS
Director, Division of Neuro-Oncology and Skull-Base Surgery
Department of Neurosurgery
Hackensack University Medical Center
Hackensack, NJ

Disclosures: No relevant financial relationships with ineligible companies.

James L. Rubenstein, MD, PhD
Professor of Medicine
Division of Hematology/Oncology
University of California, San Francisco
San Francisco, CA

Disclosures: Grant/Research Support: Celgene, Genentech, Kymera Therapeutics.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.